home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.230 +0.050 (+4.24%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

36 37 Next >

48 Stocks Moving In Friday's Mid-Day Session ↗

November 26, 2021

Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded...

Via Benzinga

OCGN Stock Alert: The FDA News Sending Ocugen Plummeting Today ↗

November 26, 2021

Shares of OCGN stock are under pressure after the FDA halted the approval process of Covaxin, a major setback for Ocugen.

Via InvestorPlace

Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold ↗

November 26, 2021

The FDA has issued a clinical hold on Ocugen Inc's (NASDAQ: OCGN) Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate,...

Via Benzinga

25 Stocks Moving in Friday's Pre-Market Session ↗

November 26, 2021

Gainers iSpecimen Inc. (NASDAQ: ISPC) rose 56.9% to $16.00 in pre-market trading. The company recently announced it has been contracted to support new advanced research on COVID-...

Via Benzinga

3 Small-Cap COVID Stocks With Huge Upside ↗

November 25, 2021

Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics.

Via The Motley Fool

Think Twice Before You Roll the Dice on Ocugen Stock ↗

November 24, 2021

OCGN stock may spike once again on positive news, but investors' best best is to steer clear of it at this point in time.

Via InvestorPlace

Ocugen-Partnered Bharat Biotech's COVID-19 Shot Shows 50% Effectiveness In Small Study In India ↗

November 24, 2021

Bharat Biotech's vaccine was found to be 50% effective at preventing symptomatic COVID-19 in a high-risk population during the second wave of infections in India this year,...

Via Benzinga

Better Buy: Ocugen or Novavax? ↗

November 24, 2021

Will either of these hopeful vaccine makers continue to thrash the market?

Via The Motley Fool

Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen ↗

November 21, 2021

Both vaccine makers still have big hurdles to jump.

Via The Motley Fool

Ocugen Stock: Bull vs. Bear ↗

November 20, 2021

There's more to this potential coronavirus vaccine stock than what happens in the next 12 months.

Via The Motley Fool

Why Ocugen Shot 8% Higher on Friday ↗

November 19, 2021

There was some highly encouraging news about coronavirus vaccines, but not the one the company is associated with.

Via The Motley Fool

The Slide in Ocugen Could Be a Slide to a Homerun ↗

November 19, 2021

Ocugen has potential for its gene therapy treatment for eye diseases, but OCGN stock movement has been all about Covaxin.

Via InvestorPlace

Why This Meme Stock Isn't Worth the Trouble ↗

November 18, 2021

This biotech is targeting a lucrative market, but it may be too late for the company.

Via The Motley Fool

3 Biotech Stocks That Have More Than Tripled so far This Year ↗

November 18, 2021

But can they keep up the momentum?

Via The Motley Fool

2 More Stocks Set to 2x… 5x… 10x in 2022 ↗

November 17, 2021

Finding 10x stocks is possible; it's simply a matter of knowing what patterns to look for. Here are a couple of strong contenders.

Via InvestorPlace

Topics Economy

3 Things About Ocugen That Smart Investors Know ↗

November 17, 2021

Revenue may not be right around the corner.

Via The Motley Fool

Ocugen Proves Groupthink Is a Double-Edged Sword ↗

November 17, 2021

While OCGN stock is an intriguing idea on the science, when the masses have a different framework, it becomes a risky proposition.

Via InvestorPlace

Ocugen Needs More Than Covaxin to Boost Its Falling Shares ↗

November 16, 2021

A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices.

Via InvestorPlace

As OCGN Stock Trudges Along Without Real Hope Must Wane ↗

November 16, 2021

Ocugen is nothing but false hope despite positive news

Via InvestorPlace

Here's What Needs to Happen for Ocugen Stock to Be a Screaming Buy ↗

November 12, 2021

The company needs clear regulatory wins in the U.S. and Canada.

Via The Motley Fool

Is Ocugen About to Beat Moderna in This One Market? ↗

November 12, 2021

Ocugen aims to be among the first to carve out market share.

Via The Motley Fool

WHO’s Nod Can’t Mask Ocugen’s Flimsy Fundamentals ↗

November 11, 2021

Ocugen has been trying to commercialize a Covid-19 vaccine. However, it's facing many obstacles. Meanwhile, insiders are dumping OCGN stock.

Via InvestorPlace

7 Stocks To Sell Before They Head to The Market Graveyard ↗

November 11, 2021

So, which ones are stocks to sell ASAP? With these seven stocks, all former favorites on both Main Street and Wall Street, consider it high time to take the money and run.

Via InvestorPlace

Does Ocugen Have a Shot at Winning EUA for Its COVID Vaccine in Kids? ↗

November 10, 2021

Yes -- but the odds don't look great.

Via The Motley Fool

Ocugen, Inc. (OCGN) Q3 2021 Earnings Call Transcript ↗

November 09, 2021

OCGN earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

OCGN Stock Alert: The Earnings News That Has Ocugen Slipping Today ↗

November 09, 2021

OCGN stock is pulling back after a muted earnings report this morning, as Ocugen makes a big bet on Covaxin for kids.

Via InvestorPlace

7 Meme Stocks Ready to Regain Their Lost Momentum ↗

November 09, 2021

Aggressive investors looking to profit off of the recent impressive volatility in certain companies may want to consider these meme stocks.

Via InvestorPlace

2 Moonshots That Insiders Are Buying… and 3 They’re Not ↗

November 09, 2021

The first several days of November saw insiders spend nearly $750 million buying up shares of their companies, which is worth your attention.

Via InvestorPlace

Sell-the-News Moment Is Your Chance to Reload on Ocugen ↗

November 09, 2021

Even as OCGN stock moves backward, Ocugen's moving forward with a crucial approval

Via InvestorPlace

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com